Filing Flows › Cue Biopharma (CUE) › Who owns the stock
Who owns Cue Biopharma (CUE) stock
45 funds reported Cue Biopharma (CUE) shares in their latest 13F filings, worth $52.2M in all. The largest holder is Bleichroeder LP ($11.7M). Last quarter 44 funds added to their stakes and 2 cut them.
Largest holders (13F)
| Fund | Shares | Value | Change | Quarter |
|---|---|---|---|---|
| Bleichroeder LP | 370,682 | $11.7M | new | 2026-06-30 |
| Driehaus Capital Management LLC | 292,144 | $9.2M | new | 2026-06-30 |
| Vanguard Capital Management LLC | 161,700 | $5.1M | new | 2026-06-30 |
| Ikarian Capital, LLC | 104,364 | $3.3M | new | 2026-06-30 |
| TFG Asset Management GP | 93,819 | $3.0M | new | 2026-06-30 |
| Stempoint Capital LP | 66,995 | $2.1M | new | 2026-06-30 |
| BlackRock | 57,807 | $1.8M | new | 2026-06-30 |
| ADAR1 Capital Management, LLC | 55,193 | $1.7M | new | 2026-06-30 |
| Lion Point Capital, LP | 52,928 | $1.7M | new | 2026-06-30 |
| Squadron Capital Management LLC | 50,000 | $1.6M | new | 2026-06-30 |
| Diadema Partners LP | 48,369 | $1.5M | new | 2026-06-30 |
| Geode Capital Management, LLC | 47,824 | $1.5M | new | 2026-06-30 |
| Boothbay Fund Management, LLC | 31,459 | $993K | new | 2026-06-30 |
| UBS Group AG | 26,700 | $843K | new | 2026-06-30 |
| Citadel Advisors LLC | 25,633 | $809K | new | 2026-06-30 |
Cue Biopharma's latest quarter
Cue Biopharma, Q2 2026: revenue $7.9M (+167% year over year), net loss $153M, operating cash flow −$29.0M. The chart follows the revenue to costs, profit and cash.
Questions
Who owns the most CUE stock?
By the latest 13F filings: Bleichroeder LP ($11.7M); Driehaus Capital Management LLC ($9.2M); Vanguard Capital Management LLC ($5.1M); Ikarian Capital, LLC ($3.3M); TFG Asset Management GP ($3.0M).
What is the short interest in CUE?
792,553 shares were sold short at the 2026-10-15 settlement, 12.87% of the float.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.